SAN FRANCISCO, Nov. 5, 2019 /PRNewswire/ -- Hopelab today announced study results showing that Vivibot, a chatbot designed to support young adults following cancer treatment, can reduce anxiety

KRAKOW, Poland, Nov. 5, 2019 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU) today announced that Pawel Przewiezlikowski, Chief Executive Officer, will present a corporate overview at the following conference in Hamburg, Germany:  Event: BIO-Europe 2019, Nov.

PLEASANTON, Calif., Nov. 5, 2019 /PRNewswire/ -- SpringML Inc. ("SpringML"), a leader in Salesforce Einstein implementation services, is proud to announce its Healthcare Payer Einstein Bot to boost agent productivity and enable self-service for member questions.

MEMPHIS, Tenn., Nov. 5, 2019 /PRNewswire/ -- This holiday season, Jennifer Aniston, Sofia Vergara, Michael Strahan, Luis Fonsi, campaign newcomer Brad Paisley and many more celebrities will join

CENTER VALLEY, Pa., Nov. 5, 2019 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and urology procedures, among other core businesses, announced today its exclusive U.S. distribution agreement with Rocamed, an innovator of quality medical products, based in Monaco and a leade

COLUMBIA, Md., Nov. 5, 2019 /PRNewswire/ -- Welldoc, a leading digital health company, announced today an additional FDA-clearance for its BlueStar® digital health product. The new enhan

NEW YORK, Nov. 5, 2019 /PRNewswire/ -- Move over lengthy approval process, a new partnership between CEFALY Technology and

PARSIPPANY, N.J., Nov. 5, 2019 /PRNewswire/ -- La Quinta® by Wyndham, a trusted hotel brand among career commuters, is helping relieve stress for business travelers on November 20 – the busiest business travel day of the year – when nearly 60% more people are hitting the road than usual. According to the

LAFAYETTE, Louisiana, Nov. 5, 2019 /PRNewswire/ -- RedHawk Holdings Corp. (OTC: SNDD) ("RedHawk" or the "Company") a diversified holding company engaged in sales and distribution of medical devices, branded generic pharmaceutical drugs, commercial real estate investment and leasing, point of entry full-body security systems, and speci

TEL AVIV, Israel, Nov. 5, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) and (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today results of a Phase 2b trial assessing the efficacy of BL-8040 in combination with KEYTRUDA® (pembrolizumab)